These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 9198809)

  • 1. [New drugs in asthma treatment. Leukotriene receptor blockers and leukotriene synthesis inhibitors].
    Männistö J; Haahtela T
    Nord Med; 1997 Apr; 112(4):122-5. PubMed ID: 9198809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part I: synthesis, receptors and role of leukotrienes in asthma.
    Devillier P; Baccard N; Advenier C
    Pharmacol Res; 1999 Jul; 40(1):3-13. PubMed ID: 10378985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leukotriene E(4)-induced persistent eosinophilia and airway obstruction are reversed by zafirlukast in patients with asthma.
    Laitinen A; Lindqvist A; Halme M; Altraja A; Laitinen LA
    J Allergy Clin Immunol; 2005 Feb; 115(2):259-65. PubMed ID: 15696079
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.
    Smith LJ
    Arch Intern Med; 1996 Oct; 156(19):2181-9. PubMed ID: 8885816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Novel treatment of bronchial asthma: application of leukotriene receptor antagonists and leukotriene synthesis inhibitors].
    Diamant Z; Sterk PJ
    Ned Tijdschr Geneeskd; 1998 Jan; 142(5):72-8. PubMed ID: 12013053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of asthma with zafirlukast. Clinical experience and tolerability profile.
    Spector SL
    Drugs; 1996; 52 Suppl 6():36-46. PubMed ID: 8941502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Status of leukotrienes in the pathophysiology of asthma. Necessity for antileukotrienes treatment].
    Fal AM; Kopeć A
    Pneumonol Alergol Pol; 2010; 78(1):68-73. PubMed ID: 20162521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Leukotrienes and asthma. Clinical and experimental experiences with leukotriene receptor antagonists and leukotriene synthesis inhibitors].
    Henriksen AH; Bjermer L
    Tidsskr Nor Laegeforen; 1997 Feb; 117(5):647-51. PubMed ID: 9102953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of leukotrienes in inflammation and leukotriene inhibitors].
    Kupczyk M; Kuna P
    Pol Merkur Lekarski; 1999 Sep; 7(39):85-93. PubMed ID: 10598480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New developments in asthma therapy: how do individual leukotriene antagonists work?].
    Wagener M
    Praxis (Bern 1994); 1998 Feb; 87(8):271-5. PubMed ID: 9542455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of low dose leukotriene receptor antagonist therapy on airway remodeling and cysteinyl leukotriene expression in a mouse asthma model.
    Muz MH; Deveci F; Bulut Y; Ilhan N; Yekeler H; Turgut T
    Exp Mol Med; 2006 Apr; 38(2):109-18. PubMed ID: 16672764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leukotriene synthesis inhibitors versus antagonists: the pros and cons.
    Steinke JW; Culp JA
    Curr Allergy Asthma Rep; 2007 May; 7(2):126-33. PubMed ID: 17437683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leukotriene modifiers in pediatric asthma management.
    Bisgaard H
    Pediatrics; 2001 Feb; 107(2):381-90. PubMed ID: 11158473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial.
    Suissa S; Dennis R; Ernst P; Sheehy O; Wood-Dauphinee S
    Ann Intern Med; 1997 Feb; 126(3):177-83. PubMed ID: 9027267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leukotrienes, leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma: an update. Part II: clinical studies with leukotriene receptor antagonists and leukotriene synthesis inhibitors in asthma.
    Devillier P; Baccard N; Advenier C
    Pharmacol Res; 1999 Jul; 40(1):15-29. PubMed ID: 10378986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Zafirlukast (Accolate): a review of its pharmacological and clinical profile].
    Murata Y; Sugimoto O
    Nihon Yakurigaku Zasshi; 2002 Apr; 119(4):247-58. PubMed ID: 11979731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced prostaglandin E2 secretion in sputum from asthmatic patients after zafirlukast therapy.
    Tsai JJ; Su YC; Chan SC; Ho CK; Feng TC
    J Formos Med Assoc; 2001 Apr; 100(4):241-3. PubMed ID: 11393122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antileukotriene agents.
    Tan RA; Spector SL
    Curr Opin Pulm Med; 1997 May; 3(3):215-20. PubMed ID: 9232368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast.
    Sampson AP; Siddiqui S; Buchanan D; Howarth PH; Holgate ST; Holloway JW; Sayers I
    Thorax; 2000 Oct; 55 Suppl 2(Suppl 2):S28-31. PubMed ID: 10992553
    [No Abstract]   [Full Text] [Related]  

  • 20. New approaches to anti-inflammatory therapy for asthma.
    Wenzel SE
    Am J Med; 1998 Mar; 104(3):287-300. PubMed ID: 9552092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.